1. Assessing the Impact: New Data in T790+ NSCLC

4. Lung Cancer Leading Cause of Cancer-Related Mortality Worldwide

5. Frequency of Genomic Alterations in NSCLC

6. Treatment of Patients With Newly Diagnosed Advanced EGFR+ NSCLC

7. Case Initial Presentation and Treatment

8. Considerations for Treatment at Progression

9. NSCLC: Progressive Disease

10. Rebiopsy at Time of Progression When and How?

11. Plasma Biopsy

12. Plasma Testing vs Tissue Testing A Tale of 2 Imperfect Tests

13. Case (cont) Disease Progression: What Are Her Options?

14. Erlotinib Until and Beyond Progression in Asian Patients With EGFR+ NSCLC ASPIRATION Study

15. Gefitinib + Chemotherapy After Progression on Gefitinib IMPRESS Study

16. Case (cont) Started On Osimertinib

17. AURA3: Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer Osimertinib Superior To Chemotherapy

18. AURA3 Results Patients With CNS Metastases

19. Osimertinib: Intracranial Response Rate in CNS Metastases Results From a Pooled Analysis

20. Osimertinib in Leptomeningeal Disease Preliminary Results of the BLOOM Study

21. Osimertinib as Front-Line Treatment in EGFR+ NSCLC Results From AURA Study

22. Questions About T790M in the Treatment-Naive Patient

23. Osimertinib: First-line EGFR MT Study: FLAURA

24. Other Third-Generation EGFR TKIs in Development for Front-Line Therapy in NSCLC

25. Concluding Remarks

26. Abbreviations

27. Abbreviations (cont)